Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Rating) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 402,600 shares, a growth of 39.7% from the December 31st total of 288,200 shares. Based on an average daily trading volume, of 340,300 shares, the short-interest ratio is presently 1.2 days.
Analyst Ratings Changes
Separately, Jonestrading started coverage on shares of Plus Therapeutics in a research report on Thursday, October 6th. They issued a "buy" rating and a $5.00 target price for the company.
Get
Plus Therapeutics alerts:
Hedge Funds Weigh In On Plus Therapeutics
Several large investors have recently made changes to their positions in PSTV. Vanguard Group Inc. boosted its position in shares of Plus Therapeutics by 20.0% during the 1st quarter. Vanguard Group Inc. now owns 855,264 shares of the company's stock valued at $855,000 after purchasing an additional 142,417 shares in the last quarter. Otter Creek Advisors LLC boosted its holdings in shares of Plus Therapeutics by 293.5% in the second quarter. Otter Creek Advisors LLC now owns 330,168 shares of the company's stock worth $178,000 after buying an additional 246,267 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Plus Therapeutics by 50.1% in the second quarter. Renaissance Technologies LLC now owns 101,093 shares of the company's stock worth $55,000 after buying an additional 33,735 shares during the period. Institutional investors own 10.52% of the company's stock.
Plus Therapeutics Price Performance
Shares of NASDAQ:PSTV traded up $0.01 during trading hours on Friday, hitting $0.44. 207,287 shares of the company's stock traded hands, compared to its average volume of 366,921. Plus Therapeutics has a 52 week low of $0.29 and a 52 week high of $1.20. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.81 and a current ratio of 2.81. The company's fifty day simple moving average is $0.38 and its two-hundred day simple moving average is $0.50. The company has a market cap of $14.86 million, a price-to-earnings ratio of -0.50 and a beta of 0.42.
Plus Therapeutics Company Profile
(Get Rating)
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Recommended Stories
- Get a free copy of the StockNews.com research report on Plus Therapeutics (PSTV)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
